Search Results - resistant

6 Results

Sort By:

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Abstract: Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor....

Published: 5/22/2024 | Inventor(s): Md Alam, De Yang, Joost Oppenheim

Keywords(s): cGAMP, Combination Therapy, FSL-1, HMGN1, Immune Checkpoint Inhibitor, Immunotherapy, Melanin-Producing Melanoma, MELANOMA, Oppenheim, RESISTANT, STING Agonist, TLR, TLR2/6, TLR4, TLR4 Agonist, Toll-like receptor, TRL2/6 Agonist

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance

CDC researchers have developed a patented set of RT-PCR and sequencing primers based on HIV-1 group M sequences. Evaluation of the primers using samples collected around the world demonstrated broad detection capacity for multiple HIV-1 group subtypes and predominant circulating recombinant forms. Commercially available HIV-1 drug resistance (HIVDR)...

Published: 7/25/2024 | Inventor(s): Joshua Devos, Nicholas Wagar, Zhiyong Zhou, Chunfu Yang

Keywords(s): AIDS, assay, blood-borne, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DGHA, DA4AXX, DA4XXX, DAXXXX, DEVELOPING, Diagnosis, diagnostic, DRUG, drug resistance, drug resistant, DXXXXX, EMERGING, EPIDEMIOLOGIC, Genotype, Genotyping, Global, HIV, HIV-1, Listed LPM Houze as of 4/15/2015, PCR, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resistance, RESISTANT, RT-PCR, Surveillance, therapeutic, tropical, viral, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Diagnostics

Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors

Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced biological activity of ALDHs has been associated with a variety of disease states such as alcoholic liver disease, Parkinson’s disease, obesity, and Cancer. Increased expression of ALDH1A1...

Published: 7/25/2024 | Inventor(s): Anton Simeonov, David Maloney, Natalia Martinez, Adam Yasgar, Shyh-Ming Yang

Keywords(s): 1A1, 3D spheroid, ALDEFLUOR assay, Aldehyde, ALDH, ALDH1A1, cancer stem cells, combined treatment, DEHYDROGENASE, high-content imaging, high-throughput screening, Inhibitors, liver, METABOLIC, MOLECULE, OBESITY, OV-90, Parkinson, RESISTANT, SKOV-3, Small

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis

CDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of Mycobacterium tuberculosis and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting M. tuberculosis and determining...

Published: 7/25/2024 | Inventor(s): Jonas Winchell, Kelley Cowart, Melissa Ramirez, James Posey

Keywords(s): analysis, DA3XXX, DAXXXX, Detection, DXXXXX, High, Melt, Multidrug, PCR, PROCESS, REAL-TIME, RESISTANT, RESOLUTION, TUBERCULOSIS, Tuberculosis (Mycobacterium tuberculosis)

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Diagnostics

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology

Method of Diagnosing Multidrug Resistant Tuberculosis

The invention can be used to develop tests that are much more rapid than conventional tests for determining drug resistance. It relates to the discovery that a putative gene of Mycobacterium tuberculosis (MTb) with no previously identified function is responsible for the ability of the bacteria to activate a class of second line thioamide drugs used...

Published: 7/25/2024 | Inventor(s): Andrea Debarber, Khisimuzi Mdluli, Clifton Barry

Keywords(s): DA3XXX, DAXXXX, DB3XXX, DBXXXX, DIAGNOSING, Duke DNA Project, DXXXXX, Methods, Multidrug, RESISTANT, TUBERCULOSIS, Tuberculosis (Mycobacterium tuberculosis), UA1XXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics